Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Top Cited Papers
Open Access
- 1 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (2), ofab050
- https://doi.org/10.1093/ofid/ofab050
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.Keywords
This publication has 3 references indexed in Scilit:
- Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies First Results From the RCT DUPLICATE InitiativeCirculation, 2020
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19JAMA, 2020
- Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsisScience Translational Medicine, 2019